| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CP51; CP51A_HUMAN; CYP51; CYP51A1; CYPL1; CYPLI; Cytochrome P450 51; Cytochrome P450 51A1; Cytochrome P450 family 51 subfamily A member 1; Cytochrome P450 family 51 subfamily A polypeptide 1; Cytochrome P450; 51 (lanosterol 14 alpha demethylase); Cytochrome P450-14DM; Cytochrome P45014DM; Cytochrome P450LI; Lanosterol 14-alpha demethylase; LDM; P450 14DM; P450L1; Sterol 14-alpha demethylase |
| Clonality | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Immunogen | Recombinant Human Lanosterol 14-alpha demethylase protein (270-437AA) |
| Isotype | |
| Product Type | |
| Reactivity | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Storage | |
| Target | |
| UniProt # |
Overview
This polyclonal anti-CYP51A1 antibody raised in Rabbit, tested in ELISA, WB, IHC. Designed to detect CYP51A1 in Human for cardiovascular research.
Key elements and design rationale
- Immunogen: Recombinant Human Lanosterol 14-alpha demethylase protein (270-437AA) — determines epitope; confirm sample prep compatibility.
- Host (Rabbit): Requires anti-rabbit-IgG secondary matching isotype IgG.
- Polyclonal: Multiple epitopes = robust signal; lot-to-lot variability — include controls.
- Isotype (IgG): Match secondary, Protein A/G, and isotype controls to IgG.
- Purification (Protein G purification): Enriches Ig classes; reduces non-specific background.
Biological background
CYP51A1 (also: CP51, CP51A_HUMAN, CYP51, CYP51A1, CYPL1, CYPLI, Cytochrome P450 51, Cytochrome P450 51A1, Cytochrome P450 family 51 subfamily A member 1, Cytochrome P450 family 51 subfamily A polypeptide 1, Cytochrome P450, 51 (lanosterol 14 alpha demethylase), Cytochrome P450-14DM, Cytochrome P45014DM, Cytochrome P450LI, Lanosterol 14-alpha demethylase, LDM, P450 14DM, P450L1, Sterol 14-alpha demethylase) — studied in Human systems. Expression, localization, and PTMs vary across cell types and disease states. Consult UniProt, NCBI Gene, and primary literature for current CYP51A1 annotation relevant to cardiovascular.
Common research applications
- ELISA: Quantify soluble target; ensure samples within the linear detection range.
- WB: Confirms MW, distinguishes isoforms under denaturing conditions.
- IHC: Tissue expression in FFPE/frozen sections; optimize antigen retrieval.
Notes for experimental interpretation
- Isotype controls: IgG from Rabbit at equivalent concentration.
- Cross-reactivity: Polyclonal: validate with KO/KD controls.
- Matrix effects: Verify dilution linearity in your sample matrix.
- Reactivity: Confirmed for Human; extrapolation requires validation.
This product is a polyclonal antibody purified from rabbit antiserum.
CYP51A1 is a protein studied in Human biology. This polyclonal antibody raised in Rabbit detects CYP51A1 in ELISA, WB, IHC applications, IgG isotype.
Reported reactive against Human. Immunogen from Human. Cross-reactivity with untested species requires empirical confirmation.
Reported for ELISA, WB, IHC. Optimize dilution/blocking per application. Consult datasheet for working concentrations.
Non-conjugated IgG; requires anti-rabbit-IgG secondary conjugated to your preferred reporter (HRP, AP, fluorophore, or biotin).
(1) Isotype control: IgG from Rabbit; (2) Positive control: lysate/cell line expressing CYP51A1; (3) Negative control: siRNA KD or KO; (4) Dilution linearity in your sample matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
